{"classes":[{"categories":[{"measurements":[{"comment":"Upper end confidence interval is not estimable because the number of events beyond the median, and their timing, does not permit calculation of the upper confidence interval.","groupId":"OG000","lowerLimit":"13.2","upperLimit":"NA","value":"14.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"}],"units":"Participants"}],"description":"Overall survival is time from treatment start date until date of death or date last known alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Combination chemo and biological therapy\n\nRituximab: 2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5\n\nFilgrastim: Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle\n\nEtoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride (EPOCH): combination chemotherapy: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles","id":"OG000","title":"Arm 1-Combination Chemo and Biological Therapy"}],"paramType":"MEDIAN","populationDescription":"One participant declined to participate before treatment started.","reportingStatus":"POSTED","timeFrame":"The participants were followed for survival for a median of 15.4 years.","title":"Median Overall Survival","type":"SECONDARY","unitOfMeasure":"years"}